Skip to content
E2 · Observational studyCohortPEM unclearObservationalPeer-reviewed
Standard · 3 min

Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome.

Rekeland, Ingrid G, Fluge, Øystein, Alme, Kine et al.

Clinical therapeutics2019DOIPubMed

Design
Observational
Participants
Not reported
PEM required
Unclear
Case definition
Not stated in the abstract

Quick Summary

This study looked at whether the amount of a drug called rituximab in patients' blood predicted whether they would improve from ME/CFS symptoms. The researchers measured rituximab levels in 23 patients and found no clear connection between how much drug was in the blood and who felt better. Interestingly, none of the patients developed antibodies against the drug, which was a potential concern.

Why It Matters

Understanding whether drug levels in the blood correlate with treatment benefit is crucial for evaluating whether rituximab is truly effective for ME/CFS or whether negative results reflect inadequate drug exposure. This study helps clarify the mechanisms of rituximab response and suggests that if this drug works for ME/CFS, it may not depend simply on achieving certain blood concentrations.

Observed Findings

What the study reports it measured.

  • No significant difference in mean serum rituximab concentrations between 14 clinical responders and 9 non-responders.
  • No patients developed anti-rituximab antibodies (ADAs) at any timepoint during treatment.
  • Female patients had significantly higher mean serum rituximab concentrations than male patients at 3 months (P = 0.05).
  • Significant negative correlation between baseline B-cell numbers and rituximab concentration at 3 months (r = -0.47; P = 0.03).

Inferred Conclusions

What the authors interpret from those results.

  • Clinical improvement in ME/CFS patients was not associated with rituximab serum concentrations or development of ADAs.
  • The mechanism of any rituximab benefit in ME/CFS, if present, does not appear to depend on achieving particular drug blood levels.
  • Rituximab pharmacokinetic measurements provide supplementary information but may have limited value for explaining trial outcomes in ME/CFS.

Remaining Questions

  • Why do some patients show clinical improvement while others do not if drug concentrations are similar, and what alternative mechanisms might explain any therapeutic benefit?
  • Do sex-based differences in rituximab concentrations have clinical relevance, and are they related to pharmacokinetics or other biological factors?
  • How do baseline B-cell characteristics beyond absolute numbers influence rituximab response in ME/CFS?
  • Should future rituximab trials in ME/CFS employ different dosing strategies, patient selection criteria, or outcome measures to better evaluate efficacy?

What This Study Does Not Prove

This study does not prove rituximab is ineffective for ME/CFS—only that drug concentration levels alone do not explain which patients improve and which do not. The observational design prevents causal inference about rituximab efficacy, and the small sample size limits generalizability. The findings also do not rule out other mechanisms of action or potential value in larger, more carefully controlled trials.

Explore further

About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →

Cite this study

The first block is for the primary paper and is the citation you should use in research work. The atlas-snapshot line only applies if you are specifically referring to this atlas’s reading of the paper on the date shown.

Primary citation

Rekeland, Ingrid G, Fluge, Øystein, Alme, Kine, Risa, Kristin, Sørland, Kari, Mella, Olav, et al. (2019). Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome.. Clinical therapeutics. https://doi.org/10.1016/j.clinthera.2018.10.019

BibTeX

@article{mecfsatlas-rekeland-2019-rituximab-serum,
  author  = {Rekeland, Ingrid G and Fluge, Øystein and Alme, Kine and Risa, Kristin and Sørland, Kari and Mella, Olav and de Vries, Annick and Schjøtt, Jan},
  title   = {Rituximab Serum Concentrations and Anti-Rituximab Antibodies During B-Cell Depletion Therapy for Myalgic Encephalopathy/Chronic Fatigue Syndrome.},
  journal = {Clinical therapeutics},
  year    = {2019},
  doi     = {10.1016/j.clinthera.2018.10.019},
  note    = {PubMed: 30502905},
  url     = {https://www.mecfsatlas.com/evidence/rekeland-2019-rituximab-serum},
}

Atlas snapshot reference

ME/CFS Atlas. Generator v1 / Scanner v1.4 / policy v0.1. Accessed 2026-11-14. https://www.mecfsatlas.com/evidence/rekeland-2019-rituximab-serum

Contribute

Private, reviewed by a human. Not a public comment thread.